-+ 0.00%
-+ 0.00%
-+ 0.00%

LEADS BIOLABS’ OPAMTISTOMIG (PD-L1/4-1BB BISPECIFIC ANTIBODY) PHASE II CLINICAL STUDY FOR FIRST-LINE TREATMENT OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA ADVANCES TO EXPANSION STAGE

Reuters·08/25/2026 02:25:02

Please log in to view news